The ASICS trial is a non-inferiority, single-arm trial open to both breast-conserving and mastectomy patients in which no SLNB is performed in cN0, triple-negative, or HER2-positive breast cancer patients with a radiological complete response on MRI (30). Here, ERBB2 is linked to breast cancer.